eosinophilic asthma

Mepolizumab (SB 240563) is a humanized monoclonal antibody that neutralizes IL-5, and can be utilized in research on severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.

S-Y048 is an Oxoeicosanoid (OXE) receptor antagonist that inhibits allergen-induced eosinophil infiltration into the skin of experimentally sensitized rhesus monkeys to house dust mites and inhibits lung inflammation caused by aerosolized allergen challenge. S-Y048 can be used to study asthma and other eosinophilic diseases.

Lyn peptide inhibitor acetate is a potent and cell-permeable inhibitor of Lyn-coupled IL-5 receptor signaling pathway, while keeping other signals intact. Lyn peptide inhibitor blocks Lyn activation and inhibits the binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors. Lyn peptide inhibitor can be used for study of asthma, allergic, and other eosinophilic disorders.

Benralizumab (MEDI-563) is a monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα). It enhances antibody-dependent cell-mediated cytotoxicity, leading to a rapid depletion of eosinophils. Benralizumab is used for severe eosinophilic asthma and can be employed to prevent exacerbations of chronic obstructive pulmonary disease.

GW 766994 is a selective, orally active CCR3 (chemokine receptor-3) antagonist (Ki=13.8 nM) with anti-inflammatory effects, suitable for studying asthma and eosinophilic bronchitis.

Histamine glutarimide is a novel small molecule agent functioning as an inhibitor of glutaminyl-peptide cyclotransferase (QPCT), which targets key inflammatory processes including eosinophilic migration and mast cell degranulation, Histamine glutarimide has demonstrated significant anti-asthmatic effects in various preclinical animal models of allergic asthma.

BMS-639623 is a CCR3 antagonist with a picomolar inhibitory effect on eosinophilic chemotaxis and can be used in the treatment of asthma.

Lyn Peptide Inhibitor TFA is a powerful, cell-permeable inhibitor specifically targeting the Lyn-coupled IL-5 receptor signaling pathway, without affecting alternative signaling pathways. It effectively prevents Lyn activation and impedes the association between Lyn tyrosine kinase and the βc subunit of IL-3/GM-CSF/IL-5 receptors. This compound is utilized in the investigation of asthma, allergic reactions, and various eosinophilic conditions [1].

SHR-1703 is a long-acting humanized anti-IL-5 IgG1 monoclonal antibody. It selectively identifies and binds to IL-5, preventing IL-5 from associating with the α chain of eosinophil surface receptors. This action inhibits the proliferation, activation, and migration of eosinophils, ultimately reducing eosinophil-mediated inflammation and damage. SHR-1703 is applicable for research into eosinophil-related diseases, such as eosinophilic asthma. The recommended isotype control is HumanIgG1kappa, Isotype Control.

Cell-permeable inhibitor of Lyn-dependent effects of the IL-5 receptor. Blocks binding of Lyn tyrosine kinase to βc subunit of IL-3/GM-CSF/IL-5 receptors, blocking Lyn activation. Inhibits IL-5 receptor-mediated eosinophil differentiation and survival in